Literature DB >> 29850970

Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.

Min Pan1, QiongXiu Zhou2, ShuBei Zheng1, XiaoHan You2, Duo Li2, Ji Zhang2, ChaoSheng Chen2, FeiFei Xu2, ZhanYuan Li1, ZhiHong Zhou1, JianNa Zhang3.   

Abstract

IgA nephropathy (IgAN) is an autoimmune disease associated with complement activation. It is unclear whether the ratio of serum C3 and C4 concentrations (C3/C4 ratio) can predict renal outcomes in IgAN patients. A total of 1503 patients diagnosed with IgAN via renal biopsy were recorded in this study. Poor renal outcomes were defined as > 50% decrease in the baseline estimated glomerular filtration rate (eGFR) or development of end-stage renal disease (ESRD) during follow-up. In total, 712 patients meeting the exclusion/inclusion criteria were selected, and the mean follow-up period was 40.6 (12.34) months. Patients with decreased C3/C4 ratios displayed significantly more severe clinical characteristics and renal pathological features and a higher proportion of poor renal outcomes and ESRD. The optimal multivariate Cox regression models identified the C3/C4 ratio (hazard ratio (HR) 0.63, 95% CI 0.5-0.9), serum uric acid (HR 1.58, 95% CI 1.2-2.2), serum creatinine (HR 1.3, 95% CI 1.1-1.6), systolic blood pressure (HR 1.57, 95% CI 1.2-2.0) and T score (relative to T0, T1: HR 1.96, 95% CI 1.1-3.7, T2: HR 3.03, 95% CI 1.6-5.9) as strong predictors of poor renal outcomes. Subgroup analysis showed that patients with low C3/C4 ratios benefited from glucocorticoids or other immunosuppressive agents (hazard ratio 0.30 and 0.18, 95% CI 0.13-0.72 and 0.07-0.46, respectively). Serum C3/C4 ratios may be an independent novel predictor of renal outcomes in IgAN patients. Decreased C3/C4 ratios suggest poor renal outcomes and the potential to benefit from aggressive immunosuppressive therapies.

Entities:  

Keywords:  Chronic kidney disease; Complement; IgA nephropathy; Oxford classification; Predictive marker

Mesh:

Substances:

Year:  2018        PMID: 29850970     DOI: 10.1007/s12026-018-8995-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  38 in total

1.  Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index.

Authors:  Yan Yang; Erwin K Chung; Bi Zhou; Carol A Blanchong; C Yung Yu; George Füst; Margit Kovács; Agnes Vatay; Csaba Szalai; István Karádi; Lilian Varga
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

Review 2.  The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches?

Authors:  Jürgen Floege
Journal:  Am J Kidney Dis       Date:  2011-08-26       Impact factor: 8.860

3.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

4.  Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up.

Authors:  Gen-yang Cheng; Dong-wei Liu; Na Zhang; Lin Tang; Zhan-zheng Zhao; Zhang-suo Liu
Journal:  Clin Nephrol       Date:  2013-07       Impact factor: 0.975

5.  Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

Authors:  Jicheng Lv; Hong Zhang; Muh Geot Wong; Meg J Jardine; Michelle Hladunewich; Vivek Jha; Helen Monaghan; Minghui Zhao; Sean Barbour; Heather Reich; Daniel Cattran; Richard Glassock; Adeera Levin; David Wheeler; Mark Woodward; Laurent Billot; Tak Mao Chan; Zhi-Hong Liu; David W Johnson; Alan Cass; John Feehally; Jürgen Floege; Giuseppe Remuzzi; Yangfeng Wu; Rajiv Agarwal; Hai-Yan Wang; Vlado Perkovic
Journal:  JAMA       Date:  2017-08-01       Impact factor: 56.272

Review 6.  New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.

Authors:  Riccardo Magistroni; Vivette D D'Agati; Gerald B Appel; Krzysztof Kiryluk
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

7.  Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study.

Authors:  Min Pan; Ji Zhang; Zhanyuan Li; Lingwei Jin; Yu Zheng; Zhihong Zhou; Su Zhen; Guoyuan Lu
Journal:  BMC Nephrol       Date:  2017-07-11       Impact factor: 2.388

8.  Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population.

Authors:  Jie Wu; Ling Qiu; Xin-Qi Cheng; Tao Xu; Wei Wu; Xue-Jun Zeng; Yi-Cong Ye; Xiu-Zhi Guo; Qian Cheng; Qian Liu; Li Liu; Cheng-Li Xu; Guang-Jin Zhu
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

Review 9.  The complement cascade and renal disease.

Authors:  Katarzyna Kościelska-Kasprzak; Dorota Bartoszek; Marta Myszka; Marcelina Zabińska; Marian Klinger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-09-13       Impact factor: 4.291

10.  Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy.

Authors:  Jingjing Zhou; Yuqing Chen; Ying Liu; Sufang Shi; Xueying Li; Suxia Wang; Hong Zhang
Journal:  BMC Nephrol       Date:  2014-01-14       Impact factor: 2.388

View more
  3 in total

1.  Glomerular C4 deposition and glomerulosclerosis predict worse renal outcomes in Chinese patients with IgA nephropathy.

Authors:  Yan Yang; Xi Tang; Yuan Yang; Xinrui Li; Lingzhi Li; Kai Huang; Yi Li; Jing Li; Ping Fu
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

2.  The clinical and pathological characteristics of IgA nephropathy patients in Tibet.

Authors:  Fenglei Si; Jiarong Mei; Yong A; Chen Tang; Yuxuan Yao; Lijun Liu
Journal:  BMC Nephrol       Date:  2022-07-27       Impact factor: 2.585

3.  Relationship between serum C3/C4 ratio and prognosis of immunoglobulin A nephropathy based on propensity score matching.

Authors:  Yan Zhang; Shu-Wei Duan; Pu Chen; Zhong Yin; Yong Wang; Guang-Yan Cai; Xiang-Mei Chen
Journal:  Chin Med J (Engl)       Date:  2020-03-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.